208 related articles for article (PubMed ID: 11728926)
1. Inhibition of bone resorption by alendronate and risedronate does not require osteoclast apoptosis.
Halasy-Nagy JM; Rodan GA; Reszka AA
Bone; 2001 Dec; 29(6):553-9. PubMed ID: 11728926
[TBL] [Abstract][Full Text] [Related]
2. Bisphosphonates act directly on the osteoclast to induce caspase cleavage of mst1 kinase during apoptosis. A link between inhibition of the mevalonate pathway and regulation of an apoptosis-promoting kinase.
Reszka AA; Halasy-Nagy JM; Masarachia PJ; Rodan GA
J Biol Chem; 1999 Dec; 274(49):34967-73. PubMed ID: 10574973
[TBL] [Abstract][Full Text] [Related]
3. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras.
Luckman SP; Hughes DE; Coxon FP; Graham R; Russell G; Rogers MJ
J Bone Miner Res; 1998 Apr; 13(4):581-9. PubMed ID: 9556058
[TBL] [Abstract][Full Text] [Related]
4. Involvement of vacuolar H+ -ATPase in incorporation of risedronate into osteoclasts.
Takami M; Suda K; Sahara T; Itoh K; Nagai K; Sasaki T; Udagawa N; Takahashi N
Bone; 2003 Apr; 32(4):341-9. PubMed ID: 12689676
[TBL] [Abstract][Full Text] [Related]
5. Visualization of bisphosphonate-induced caspase-3 activity in apoptotic osteoclasts in vitro.
Benford HL; McGowan NW; Helfrich MH; Nuttall ME; Rogers MJ
Bone; 2001 May; 28(5):465-73. PubMed ID: 11344045
[TBL] [Abstract][Full Text] [Related]
6. Antagonistic effects of different classes of bisphosphonates in osteoclasts and macrophages in vitro.
Frith JC; Rogers MJ
J Bone Miner Res; 2003 Feb; 18(2):204-12. PubMed ID: 12568397
[TBL] [Abstract][Full Text] [Related]
7. Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro.
Fisher JE; Rogers MJ; Halasy JM; Luckman SP; Hughes DE; Masarachia PJ; Wesolowski G; Russell RG; Rodan GA; Reszka AA
Proc Natl Acad Sci U S A; 1999 Jan; 96(1):133-8. PubMed ID: 9874784
[TBL] [Abstract][Full Text] [Related]
8. Protein geranylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298.
Coxon FP; Helfrich MH; Van't Hof R; Sebti S; Ralston SH; Hamilton A; Rogers MJ
J Bone Miner Res; 2000 Aug; 15(8):1467-76. PubMed ID: 10934645
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of inflammatory and bone-resorption-inhibitory effects of alendronate by etidronate.
Funayama H; Ohsako M; Monma Y; Mayanagi H; Sugawara S; Endo Y
Calcif Tissue Int; 2005 Jun; 76(6):448-57. PubMed ID: 15895282
[TBL] [Abstract][Full Text] [Related]
10. BM 21.0955, a potent new bisphosphonate to inhibit bone resorption.
Mühlbauer RC; Bauss F; Schenk R; Janner M; Bosies E; Strein K; Fleisch H
J Bone Miner Res; 1991 Sep; 6(9):1003-11. PubMed ID: 1838661
[TBL] [Abstract][Full Text] [Related]
11. Risedronate directly inhibits osteoclast differentiation and inflammatory bone loss.
Kwak HB; Kim JY; Kim KJ; Choi MK; Kim JJ; Kim KM; Shin YI; Lee MS; Kim HS; Kim JW; Chun CH; Cho HJ; Hong GY; Juhng SK; Yoon KH; Park BH; Bae JM; Han JK; Oh J
Biol Pharm Bull; 2009 Jul; 32(7):1193-8. PubMed ID: 19571384
[TBL] [Abstract][Full Text] [Related]
12. Bisphosphonate therapy.
Licata AA
Am J Med Sci; 1997 Jan; 313(1):17-22. PubMed ID: 9001162
[TBL] [Abstract][Full Text] [Related]
13. In vivo effects of bisphosphonates on the osteoclast mevalonate pathway.
Fisher JE; Rodan GA; Reszka AA
Endocrinology; 2000 Dec; 141(12):4793-6. PubMed ID: 11108295
[TBL] [Abstract][Full Text] [Related]
14. Distinguishing the proapoptotic and antiresorptive functions of risedronate in murine osteoclasts: role of the Akt pathway and the ERK/Bim axis.
Matsumoto T; Nagase Y; Iwasawa M; Yasui T; Masuda H; Kadono Y; Nakamura K; Tanaka S
Arthritis Rheum; 2011 Dec; 63(12):3908-17. PubMed ID: 21898348
[TBL] [Abstract][Full Text] [Related]
15. Effects of risedronate, alendronate, and etidronate on the viability and activity of rat bone marrow stromal cells in vitro.
Still K; Phipps RJ; Scutt A
Calcif Tissue Int; 2003 Feb; 72(2):143-50. PubMed ID: 12457261
[TBL] [Abstract][Full Text] [Related]
16. The bisphosphonate tiludronate is a potent inhibitor of the osteoclast vacuolar H(+)-ATPase.
David P; Nguyen H; Barbier A; Baron R
J Bone Miner Res; 1996 Oct; 11(10):1498-507. PubMed ID: 8889850
[TBL] [Abstract][Full Text] [Related]
17. Morphological assessment of basic multicellular unit resorption parameters in dogs shows additional mechanisms of bisphosphonate effects on bone.
Allen MR; Erickson AM; Wang X; Burr DB; Martin RB; Hazelwood SJ
Calcif Tissue Int; 2010 Jan; 86(1):67-71. PubMed ID: 19953232
[TBL] [Abstract][Full Text] [Related]
18. Breast cancer cells inhibit spontaneous and bisphosphonate-induced osteoclast apoptosis.
Hussein O; Tiedemann K; Komarova SV
Bone; 2011 Feb; 48(2):202-11. PubMed ID: 20849994
[TBL] [Abstract][Full Text] [Related]
19. Binding and antiresorptive properties of heterocycle-containing bisphosphonate analogs: structure-activity relationships.
van Beek ER; Löwik CW; Ebetino FH; Papapoulos SE
Bone; 1998 Nov; 23(5):437-42. PubMed ID: 9823450
[TBL] [Abstract][Full Text] [Related]
20. The molecular mechanism of action of the antiresorptive and antiinflammatory drug clodronate: evidence for the formation in vivo of a metabolite that inhibits bone resorption and causes osteoclast and macrophage apoptosis.
Frith JC; Mönkkönen J; Auriola S; Mönkkönen H; Rogers MJ
Arthritis Rheum; 2001 Sep; 44(9):2201-10. PubMed ID: 11592386
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
